A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs - Trial NCT03078478
Access comprehensive clinical trial information for NCT03078478 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 1609 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
Phase 3
Mar 13, 2017
Mar 04, 2019
Primary Outcome
Number of Severe or BG-confirmed Symptomatic Hypoglycaemic Episodes During Maintenance 2 (36 Weeks)
Summary
This trial is conducted in Europe and North America. The aim of the trial is to compare the
 efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with
 type 2 diabetes mellitus inadequately treated with basal insulin with or without oral
 antidiabetic drugs. Due to change in glycaemic data collection process, this trial is amended
 to allow for a full 36 weeks (maintenance 2 period) of the use of the new process.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03078478
Non-Device Trial